Catheter Precision, Inc.
Business
Catheter Precision, Inc. designs, manufactures and sells medical devices focused on cardiac electrophysiology, specifically for the treatment of cardiac arrhythmias. The company's primary products are the VIVO System, a non-invasive 3D cardiac mapping platform for localizing ventricular arrhythmia origins prior to ablation procedures, and LockeT, a suture retention device for wound closure and hemostasis. The company operates through direct sales in the U.S. and indirect distribution internationally, targeting hospitals with electrophysiology labs performing approximately 600,000 ablation procedures annually.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 819,000 | 420,000 | 442,000 | 14,000 | 22,000 | |
| Cost of revenues | 63,000 | 42,000 | 30,000 | 161,000 | 2 | |
| Gross profit | 756,000 | 378,000 | 412,000 | −147,000 | −2 | |
| Selling, general and administrative | 12 | 11 | 17 | 16 | 15 | |
| Research and development | 862,000 | 272,000 | — | — | — | |
| Acquired in-process research and development | 2 | 0 | — | — | — | |
| Loss on impairment of intangible assets | 7 | 0 | — | — | — | |
| Total operating expenses | 22 | 12 | 79 | 27 | 28 | |
| Operating loss | −21 | −11 | −78 | −27 | −29 | |
| Interest income | 34,000 | 81,000 | 347,000 | — | — | |
| Change in fair value of royalties payable due to related parties | 6 | −2 | 7 | — | — | |
| Change in fair value of convertible notes payable | 2,000 | 0 | — | — | — | |
| Loss on debt extinguishment | −3 | 0 | — | — | 2 | |
| Net loss on trading debt securities | −564,000 | 0 | — | — | — | |
| Other expenses, net | −2,000 | −10,000 | −8,000 | 99,000 | −14,000 | |
| Total other income (expenses), net | 2 | −2 | 8 | 99,000 | 2 | |
| Loss from operations before income tax provision (benefit) | −20 | −14 | −71 | −27 | −27 | |
| Income tax provision (benefit) | −2 | 3 | 0 | 3,000 | 4,000 | |
| Net loss | −18 | −17 | — | — | — | |
| Less: Net loss attributable to non-controlling interest | −512,000 | 0 | — | — | — | |
| Net loss attributable to Catheter Precision, Inc. | −17 | −17 | −71 | −27 | −25 | |
| Deemed dividend on warrant inducement offer | 0 | −5 | −800,000 | — | — | |
| Net loss attributable to Catheter Precision, Inc. common stockholders | −17 | −22 | −71 | — | — | |
| Net loss per share attributable to Catheter Precision, Inc. common stockholders, basic and diluted (in dollars per share) | −15.9 | −126.91 | −129.88 | −25.98 | −248.22 | |
| Weighted-average common shares used in computing net loss per share, basic and diluted (in shares) | 1 | 171,774 | 549,507 | 1 | 101,000 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 100,000 | 3 | 4 | 16 | 15 | |
| Accounts receivable, net | 155,000 | 70,000 | 137,000 | 0 | 21,000 | |
| Inventories | 86,000 | 33,000 | 44,000 | 0 | 986,000 | |
| Prepaid expenses and other current assets | 61,000 | 316,000 | 415,000 | 977,000 | 1 | |
| Total current assets | 390,000 | 3 | 4 | 17 | 17 | |
| Property and equipment, net | 64,000 | 91,000 | 70,000 | 0 | 2 | |
| Operating lease right-of-use assets, net | 162,000 | 105,000 | 179,000 | 0 | 2 | |
| Intangible assets, net | 15 | 24 | 26 | 0 | — | |
| Other non-current assets | 8,000 | 8,000 | 8,000 | 0 | 36,000 | |
| TOTAL ASSETS | 16 | 28 | 31 | 17 | 21 | |
| Accounts payable | 1 | 230,000 | 464,000 | 92,000 | 988,000 | |
| Accrued expenses | 2 | 2 | 2 | 7 | 4 | |
| Convertible notes payable, at fair value | 298,000 | 0 | — | — | — | |
| Current portion of operating lease liabilities | 63,000 | 98,000 | 91,000 | 0 | 283,000 | |
| Total current liabilities | 4 | 2 | 2 | 8 | 5 | |
| Royalties payable due to related parties | 792,000 | 9 | 7 | — | — | |
| Operating lease liabilities | 101,000 | 13,000 | 97,000 | 0 | 2 | |
| Deferred tax liability | 1 | 3 | 0 | — | — | |
| Total liabilities | 9 | 16 | 10 | 8 | 7 | |
| Commitments and Contingencies (see Note 16) | — | — | — | — | — | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized; 1,738,955 and 421,296 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 | — | |
| Additional paid-in capital | 317 | 304 | 297 | — | — | |
| Accumulated deficit | −310 | −292 | −276 | −205 | −178 | |
| Total stockholders' equity attributable to Catheter Precision, Inc. | 7 | 12 | 21 | 9 | 14 | |
| Non-controlling interest | −403,000 | 0 | — | — | — | |
| Total stockholders' equity | 7 | 12 | 21 | — | — | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 16 | 28 | 31 | 17 | 21 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Loss on impairment of intangible assets | 7 | 0 | — | — | — | |
| Depreciation and amortization | 2 | 2 | 2 | — | — | |
| Stock-based compensation | 338,000 | 54,000 | 1 | 447,000 | 2 | |
| Net loss on trading debt securities | 564,000 | 0 | — | — | — | |
| Deferred income tax provision (benefit) | −2 | 3 | 0 | — | — | |
| Acquired in-process research and development | 2 | 0 | — | — | — | |
| Amortization of discount on note payable | 45,000 | 0 | — | — | — | |
| Accounts receivable | −85,000 | 67,000 | −66,000 | 0 | 42,000 | |
| Inventories | −78,000 | −8,000 | 8,000 | −14,000 | −197,000 | |
| Prepaid expenses and other current assets | 255,000 | 99,000 | 876,000 | −335,000 | 150,000 | |
| Operating lease right-of-use assets and lease liabilities | −4,000 | −3,000 | 4,000 | — | — | |
| Current portion of royalties payable due to related parties | 19,000 | 32,000 | 0 | — | — | |
| Accounts payable | 1 | −234,000 | −550,000 | −879,000 | 627,000 | |
| Accrued expenses | 149,000 | −185,000 | −7 | 2 | −390,000 | |
| Net cash used in operating activities | −8 | −9 | −21 | −23 | −28 | |
| Consideration paid for the acquired in-process research and development | −116,000 | 0 | — | — | — | |
| Purchases of property and equipment | −17,000 | −67,000 | −76,000 | −17,000 | −265,000 | |
| Proceeds from the sale of trading debt securities | 300,000 | 0 | — | — | — | |
| Net cash provided by (used in) investing activities | 167,000 | −67,000 | −61,000 | 21,000 | 4 | |
| Proceeds from notes payable due to related parties | 300,000 | 2 | 0 | — | — | |
| Proceeds from issuance of convertible notes payable | 300,000 | 0 | — | — | — | |
| Payments on short-term notes payable | −238,000 | −256,000 | −107,000 | 0 | — | |
| Proceeds from short-term notes payable | 61,000 | 249,000 | 0 | — | — | |
| Proceeds from exercise of warrants | 0 | 1 | 1 | 6 | — | |
| Net cash provided by financing activities | 5 | 9 | 8 | 23 | 15 | |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | −3 | −692,000 | −12 | 814,000 | −9 | |
| Cash paid for interest | 7,000 | 31,000 | 204,000 | 0 | 2,000 | |
| Property and equipment reclassified from inventories | 25,000 | 19,000 | 0 | — | — | |
| Consideration for asset acquisition included in accounts payable | 103,000 | 0 | — | — | — | |
| Extinguishment of notes payable due to related parties | 2 | 0 | — | — | — | |
| Noncash consideration issued in connection with extinguishment of notes payable due to related parties | 622,000 | 0 | — | — | — | |
| Extinguishment of royalties payable due to related parties | 3 | 0 | — | — | — | |
| Operating right-of-use asset obtained in exchange for new operating lease liabilities | 142,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Catheter Precision, Inc.'s CIK number?
Catheter Precision, Inc.'s SEC CIK number is 0001716621 (1716621). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Catheter Precision, Inc.'s SEC filings?
All of Catheter Precision, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Catheter Precision, Inc. last report earnings?
Catheter Precision, Inc. (VTAK) most recently filed an earnings 8-K with the SEC on May 18, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-017612). This is Catheter Precision, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Catheter Precision, Inc.'s most recent earnings 8-K?
Catheter Precision, Inc.'s latest earnings 8-K (Item 2.02) was filed May 18, 2026 under accession 0001437749-26-017612. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Catheter Precision, Inc.'s latest earnings 8-K →
Look up any company's CIK number →